Therapeutic Monoclonal Antibodies: ScFv Patents As a Marker of a New Class of Potential Biopharmaceuticals . Braz. J. Pharm. Sci. 2011, 47 (1), 31-38. https://doi.org/10.1590/S1984-82502011000100005.